Search

everythinglearnresearchcommunity

for

Search:↓

PRP injections with tadalafil and stretching safely improved Peyronie's symptoms but didn't significantly change curvature long-term.

Testosterone replacement therapy, especially intramuscular, raises PSA levels, but no overall link between PSA and testosterone was found except in non-BPH patients.

Finasteride may reduce prostate cancer risk.

Finasteride increases CD8+ T cells in BPH tissues.

Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.

Prostate cancer patients need early psychological and sexual support during radiotherapy to improve their quality of life.

5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.

Finasteride therapy reduces PSA levels and prostate size, helping diagnose prostate cancer.

Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.

A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Combination therapy with Finasteride is more effective than alpha-blocker alone for BPH symptoms in small prostate volume.

5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.

Finasteride reduces prostate size, improves urination, and slows prostate cancer progression.

Combining TUSV with finasteride effectively treats recurrent hemospermia.

Finasteride and levofloxacin effectively reduce chronic bacterial prostatitis severity.

5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.

Finasteride significantly reduces prostate cancer risk.

The procedure accurately measures 5-alpha-dihydrotestosterone in blood, useful for standard tests.

Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.

5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.

PSA levels help determine prostate size and guide treatment choices for benign prostatic hyperplasia.

Inhibiting testosterone 5alpha-reductase may help treat benign prostatic hyperplasia.

Taking 5-ARI before prostate laser surgery may lead to more blood changes, longer surgery, and more urinary issues.

Large prostate patients more likely to have hair loss.